QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Clinical trial NCT07009145 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07009145
Sponsor: Qianfoshan Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Colorectal Cancer Metastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer

Start date: 2025-06-27
Primary completion: 2026-06-30
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.